Ceftaroline Fosamil: A Brief Clinical Review by Debbie-Ann T. Shirley et al.
REVIEW
Ceftaroline Fosamil: A Brief Clinical Review
Debbie-Ann T. Shirley • Emily L. Heil •
J. Kristie Johnson
To view enhanced content go to www.infectiousdiseases-open.com
Received: April 25, 2013 / Published online: August 8, 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
ABSTRACT
Ceftaroline is a novel cephalosporin with a
favorable tolerability profile and broad in vitro
activity against many resistant Gram-positive
and common Gram-negative organisms.
Ceftaroline fosamil is the first cephalosporin to
be approved by the United States Food and Drug
Administration (FDA) for the treatment of
adults with acute bacterial skin and soft
tissue infections, including those caused by
methicillin-resistant Staphylococcus aureus
(MRSA). It is also approved by the FDA for the
treatment of adults with community-acquired
bacterial pneumonia, including cases caused by
Streptococcus pneumoniae (with or without
concurrent bacteremia), although there are no
data at this time to support the use of ceftaroline
fosamil for the treatment of pneumonia caused
by MRSA. Ceftaroline fosamil is likewise
approved by the European Commission for the
treatment of adults with complicated skin and
soft tissue infections or community-acquired
pneumonia. This review summarizes the
pharmacokinetic and microbiologic properties
of ceftaroline, as well as the safety and efficacy
data that led to its approval by the FDA in 2010
and the European Commission in 2012. Future
directions to be addressed are also highlighted.
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INTRODUCTION
Several authorities have called attention to the
morbidity, mortality and excess health costs
associated with antibiotic-resistant pathogens
and the need to prioritize development of
antibacterial agents that can safely and
effectively treat these pathogens [1–4].
Ceftaroline fosamil is a novel cephalosporin,
with bactericidal in vitro activity against
pathogens associated with licensed indications,
including resistant organisms, such as
methicillin-resistant Staphylococcus aureus
(MRSA), multidrug-resistant Streptococcus
pneumoniae (MDRSP) and penicillin-resistant S.
pneumoniae (PRSP) [5]. Supported by preclinical
in vitro and animal model studies [6–10] and
clinical trials [11–15], ceftaroline fosamil
(TeflaroTM; Forest Laboratories, Inc., New York,
USA) was approved by the United States Food
and Drug Administration (FDA) in October 2010
for the treatment of adults with community-
acquired bacterial pneumonia (CABP) and acute
bacterial skin and skin structure infections
(ABSSSI) caused by susceptible organisms [5].
Ceftaroline fosamil is the newest of only three
systemic antibiotics approved for human use by
the FDA over the past 5 years and the only one of
these approved for the treatment of CABP.
Similarly, the European Commission granted
marketing authorization for ceftaroline fosamil
(ZinforoTM; AstraZeneca, So¨derta¨lje, Sweden) in
August 2012 for the treatment of community-
acquired pneumonia and complicated skin and
soft tissue infections following favorable
opinion from the Committee for Medicinal
Products for Human Use [16]. This report
reviews the recent literature published on
ceftaroline fosamil, including the pivotal
clinical trials that led to its approval, and
highlights areas that need to be addressed in
the future.
MECHANISM OF ACTION
AND SPECTRUM OF ACTIVITY
Similar to other b-lactam antibiotics,
ceftaroline, the active metabolite of the
prodrug ceftaroline fosamil, mediates its
bactericidal effect by binding to membrane-
bound enzymes known as penicillin-binding
proteins (PBPs), thereby interfering with
bacterial cell wall synthesis and leading to cell
lysis and death [17]. Distinguishing it from
other b-lactam antibiotics, however, is its
unique high binding affinity for PBP 2a (which
confers resistance to MRSA) and PBP 2b, 2x and
1a (which confer resistance to PRSP) [18, 19].
The favorable activity of ceftaroline against
clinical isolates, including potent activity
against Gram-positive bacteria, such as MRSA,
vancomycin-intermediate S. aureus (VISA) and
PRSP, has been demonstrated in isolates
collected worldwide [20] with corroboration
from a number of in vitro and in vivo studies
[6, 10, 21–26], and maintained during in vitro
attempts to generate resistant strains [27, 28].
Activity against Enterococcus faecalis and
Enterococcus faecium is limited [6, 20].
Ceftaroline’s spectrum of activity against
Gram-negative bacteria is comparable to that
of many other cephalosporins, and it has no
activity against extended-spectrum b-lactamase
(ESBL) and carbapenemase-producing strains
(e.g., Klebsiella pneumonia carbapenemase) or
strains with stable de-repressed AmpC b-
lactamase production [20, 27, 29]. In vitro
activity against Gram-positive anaerobes is
similar to that of amoxicillin–clavulanate, with
good activity against Propionibacterium spp. and
Actinomyces spp. [30, 31]. Ceftaroline is inactive
against most b-lactamase-producing Gram-
negative anaerobes, including Bacteroides
fragilis and Prevotella spp. [30, 31].
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Ceftaroline minimal inhibitory
concentrations (MICs) and disk diffusion
breakpoints have been defined by the FDA,
and more recently by the Clinical Laboratory
Standards Institute (CLSI) and the European
Committee on Antimicrobial Susceptibility
Testing (EUCAST) (Table 1) [5, 32, 33]. Due to
the scarcity of resistant Gram-positive isolates at
the time of licensing, only susceptible
interpretations for Gram-positive strains are
available from the FDA [5]. Target attainment
analysis using Monte Carlo simulations support
the FDA susceptible interpretative criteria for
S. aureus (MIC B1 lg/mL) when the
recommended ceftaroline fosamil dosing
regimen is used [34]. In vivo murine thigh
infection models suggest that human simulated
exposures of ceftaroline 600 mg every 12 h may
have efficacy in the treatment of S. aureus
infections with MICs as high as 4 lg/mL [35],
but more data on clinical outcomes associated
with higher ceftaroline MICs are needed.
Results from the 2010 Assessing Worldwide
Antimicrobial Resistance Evaluation (AWARE)
program (Table 2) [36–42], a global ceftaroline
surveillance study, showed that ceftaroline is
highly active against S. aureus and MRSA among
isolates collected from medical centers in nine
United States census regions [36]. These high
rates of S. aureus susceptibility were
independent of patient age group [36]. Among
respiratory pathogens, 98.7% of S. pneumoniae
strains were inhibited by 0.25 lg/mL or less of
ceftaroline, exhibiting potency 16 times greater
than that of ceftriaxone [37]. During
2008–2010, there was sustained potency and
activity against MRSA and MDRSP [defined as a
S. pneumoniae isolate with resistance to at least
two of the following antimicrobial agents:
penicillin (C8 lg/mL), ceftriaxone,
erythromycin, tetracycline, levofloxacin, and
trimethoprim–sulfamethoxazole) and the
frequency of non-susceptibility of respiratory
pathogens to ceftaroline did not vary
significantly [37, 38]. Geographic differences
in activity among staphylococci, streptococci,
Haemophilus spp., and Moraxella catarrhalis were
minimal [39]. Susceptibility patterns to
Table 1 Food and Drug Administration (FDA), Clinical Laboratory
Standards Institute (CLSI) and European Committee on
Antimicrobial Susceptibility Testing (EUCAST) interpretive
minimum inhibitory concentration breakpoints (lg/mL) for
ceftaroline [5, 32, 33]
Organism FDAa CLSI EUCAST
S I R S I R S R
Staphylococcus aureusb B1 – – B1 2 C4 B1 [1
Streptococcus pneumoniae B0.25 – – B0.5c – – B0.25 [0.25
Streptococcus agalactiae B0.03 – – B0.5 d d
Streptococcus pyogenes B0.015 – – B0.5 – – d d
Haemophilus inﬂuenzae B0.12 – – B0.5 – – B0.03 [0.03
Enterobacteriaceae B0.5 1 C2 B0.5 1 C2 B0.5 [0.5
I intermediate, R resistant, S susceptible
a Intermediate and resistant results not deﬁned by the FDA for some pathogens
b Includes methicillin-resistant S. aureus
c Non-meningitis
d b-Lactam susceptibility of Streptococcus groups A, B, C and G is inferred from the penicillin susceptibility













































































































































































































































































































































































































































































































































































































































































































































































































































































98 Infect Dis Ther (2013) 2:95–110
123
ceftaroline among MRSA isolates from Europe,
South Africa and the Asia–Pacific region were
lower than those seen in the USA, while
consistently high rates of susceptibility to
ceftaroline by methicillin-susceptible S. aureus,
S. pneumoniae, Haemophilus influenzae and
M. catarrhalis were maintained across all these
regions [40–42]. Ongoing surveillance will be
critical to determine whether resistant strains
emerge from selective pressure elicited by more
widespread use of ceftaroline. High rates of
intermediate susceptibility of S. aureus to
ceftaroline have already been noted in vitro
among isolates from a surveillance program in
China; 36.2% of the 315 isolates tested had an
MIC above 1 lg/mL, although the highest MIC
documented was 2 lg/mL [43].
DOSE AND ADMINISTRATION
Following administration, the water-soluble
prodrug, ceftaroline fosamil, is rapidly
dephosphorylated to the active form in plasma
[17]. For adults 18 years and older, the
recommended dose is 600 mg administered
intravenously (IV) over 1 h every 12 h. A
treatment duration of 5–7 days for CABP and
5–14 days for ABSSSI is currently recommended,
guided by the severity of infection and clinical
response [5]. As with other b-lactam antibiotics,
time above the MIC is the pharmacodynamic
(PD) index that correlates best with efficacy [5].
Pharmacokinetic (PK) data in healthy adults
with normal renal function following multiple
doses administered every 12 h over 14 days
show that the elimination half-life is about
2.7 h, the maximum observed concentration
(Cmax) is 21 lg/mL and the area under the
concentration–time curve is 56 lg h/mL, with
no appreciable accumulation [5]. Ceftaroline is
primarily renally excreted and dosage
adjustment is recommended for patients with
creatinine clearance (CRCL) B50 mL/min. For
patients with moderate renal impairment (CRCL
[30 to B50 mL/min), the dose should be
adjusted to 400 mg IV every 12 h. For those
with severe renal impairment (CRCL C15 to
B30 mL/min), the dose should be adjusted to
300 mg IV every 12 h and for patients with end-
stage renal disease, including those receiving
hemodialysis, adjustment to 200 mg IV every
12 h after dialysis should be made [5].
Following a single IV radiolabeled dose,
approximately 88% of radioactivity was
recovered in urine and 6% in feces within 48 h
[5]. Of the radioactivity recovered in urine, 64%
was excreted as ceftaroline and approximately
2% as the microbiologically inactive ceftaroline
M-1 metabolite, suggesting complete
transformation of the prodrug [5]. Ceftaroline
is primarily distributed in extracellular fluid and
binding to plasma proteins is relatively low
(approximately 20%) [5]. In vitro studies
demonstrate that ceftaroline is not a substrate
for the cytochrome P450 system and it does not
inhibit or induce the major cytochrome P450
isoenzymes. Therefore, there is minimal
potential for drug–drug interactions between
ceftaroline and drugs that are cytochrome P450
substrates, inhibitors, or inducers [5].
CLINICAL EFFICACY
The FOCUS Trials
The FOCUS (ceFtarOline Community-acquired
pneUmonia trial vS ceftriaxone in hospitalized
patients) 1 and 2 studies (NCT00621504 and
NCT00509106, respectively) were multinational,
multicenter, phase 3, double-masked,
randomized, active comparator-controlled
trials, designed to evaluate the safety and
Infect Dis Ther (2013) 2:95–110 99
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efficacy of ceftaroline fosamil 600 mg IV every
12 h compared with ceftriaxone 1 g IV every 24 h
for 5–7 days for the treatment of typical CABP in
patients requiring hospital admission [12, 13, 44,
45]. Renal dose adjustments were based on
creatinine clearance. For subjects enrolled in
FOCUS 1 (which included North American
participants), clarithromycin was administered
during the first 24 h based on established
practice guidelines advocating empiric macrolide
use [46].
The primary objective of the studies was to
determine whether the clinical cure rate of
ceftaroline fosamil was non-inferior to that of
ceftriaxone in the co-primary modified intent-
to-treat efficacy (MITTE) and clinically
evaluable (CE) populations at the test-of-cure
(TOC) visit (8–15 days after completion of
therapy). The non-inferiority margin was set at
-10%. The MITTE population included all
participants in the pneumonia risk category
(PORT) III or IV who received any amount of
study drug according to their randomized
treatment group. The CE population included
participants in the MITTE population who
demonstrated sufficient adherence to the
protocol. Baseline characteristics and
demographics were comparable between the
two study arms and between the two studies.
The majority of participants were Caucasian
males over the age of 50 years recruited
from Eastern and Western Europe. The most
common pathogens isolated were S. pneumoniae
(41.7%) and S. aureus (16.5%), followed by
Gram-negative organisms, of which H.
influenzae was the most frequent [44].
Clinical cure rates favored ceftaroline in a
priori-defined integrated analysis of the MITTE
and CE populations (Table 3) [12–15, 44, 47].
Planned secondary analysis of the CE subjects
with at least one typical pathogen identified at
baseline showed clinical cure in 85.1% of
participants compared with 75.5% of
participants in the ceftaroline and ceftriaxone
groups, respectively [difference 9.7%, 95%
confidence interval (CI) 0.7–18.8%] [44]. Cure
rates against S. pneumoniae, MDRSP and S. aureus
favored ceftaroline, and were similar to
ceftriaxone for Gram-negative pathogens [44].
The efficacy of ceftaroline against MRSA could
not be evaluated as patients with suspected
MRSA infection were excluded from enrollment
(due to a lack of activity of ceftriaxone against
MRSA). For bacteremia, cure rates were 71.4%
(15 of 21 subjects) compared with 58.8% (10 of
17 subjects) for the ceftaroline and ceftriaxone
groups, respectively (difference 12.6%, 95% CI
-17.6% to 41.6%) [44]. At the late follow-up
visit (21–35 days after completion of therapy),
relapse rates between the two treatment arms
were similar in the CE population: 1.9% for the
ceftaroline group and 1.2% for the ceftriaxone
group (difference 0.7%, 95% CI -1.4% to 2.9%)
[44]. Pooled post hoc exploratory analysis
requested by the FDA to assess clinical
improvement on day 4 of study therapy in
participants with a confirmed bacterial
pathogen at baseline showed a weighted
difference in clinical response of 11.4% (95%
CI 0.6–21.9%) in favor of ceftaroline [48].
The CANVAS Trials
The CANVAS (CeftAroliNe Versus vAncomycin
in Skin and skin structure infections) 1 and 2
studies (NCT00424190 and NCT00423657,
respectively) were multinational, multicenter,
phase 3, double-masked, randomized, active
comparator-controlled trials designed to
evaluate the safety and efficacy of
monotherapy with ceftaroline fosamil 600 mg
IV every 12 h compared with a combination of
vancomycin 1 g every 12 h plus aztreonam 1 g
every 12 h IV for 5–14 days for the treatment of
100 Infect Dis Ther (2013) 2:95–110
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ABSSSI [14, 15, 45, 47] Dose adjustments for
renal impairment by unblinded pharmacists
were based on creatinine clearance and
institutional guidelines.
The primary objective of the studies was to
determine whether the clinical cure rate of
ceftaroline fosamil was non-inferior to that of
vancomycin plus aztreonam in the co-primary
modified intent-to-treat (MITT) and CE
populations at the TOC visit (8–15 days after
completion of therapy). The non-inferiority
margin was set at -10%. The MITT population
included all subjects who received any amount
of study drug according to their randomized
treatment group. The CE population included
subjects in the MITT population who
demonstrated sufficient adherence to the
protocol. Baseline characteristics and
demographics were comparable between the
two study arms in each study. The majority of
participants were Caucasian males with a
median age of 48 years diagnosed with
cellulitis, major abscesses and infected
wounds/ulcers. Of the 76% of subjects with a
pathogen isolated, S. aureus was the most
common; the proportion with MRSA was 40%
in the ceftaroline group and 34% in the
vancomycin plus aztreonam group. Aztreonam
or a saline placebo was discontinued if a Gram-
negative pathogen was not identified.
A priori-defined integrated analysis of the
primary endpoints demonstrated non-
inferiority of ceftaroline in the MITT and CE
populations (Table 3). In a planned secondary
analysis of participants in the CE population
with at least one pathogen isolated, clinical
cure was achieved in 92.7% of the subjects in
the ceftaroline treatment group compared with
Table 3 Summary of clinical cure rate at the test-of-cure visit in the co-primary analysis populations, FOCUS and
CANVAS trials [12–15, 44, 47]
Trial MITTE CE
FOCUSa Clinical cure %




(no. of cured/total no.)
Differenceb
(95% CI)
Ceftaroline Ceftriaxone Ceftaroline Ceftriaxone
1 83.8 (244/291) 77.7 (233/300) 6.2 (-0.2, 12.6) 86.6 (194/224) 78.2 (183/234) 8.4 (1.4, 15.4)
2 81.3 (235/289) 75.5 (206/273) 5.9 (-1.0, 12.7) 82.1 (193/235) 77.2 (166/215) 4.9 (-2.5, 12.5)
1 and 2 82.6 (479/580) 76.6 (439/573) 6.0c (1.4, 10.7) 84.3 (387/459) 77.7 (349/449) 6.7c (1.6, 11.8)
Trial MITT CE








Ceftaroline Vanc/Az Ceftaroline Vanc/Az
1 86.6 (304/351) 85.6 (297/347) 1.0 (-4.2, 6.2) 91.1 (288/316) 93.3 (280/300) -2.2 (-6.6, 2.1)
2 85.1 (291/342) 85.5 (289/338) -0.4 (-5.8, 5.0) 92.2 (271/294)) 92.1 (269/292) 0.1 (-4.4, 4.5)
1 and 2 85.9 (595/693) 85.5 (586/685) 0.3 (-3.4, 4.0) 91.6 (559/610) 92.7 (549/592) -1.1 (-4.2, 2.0)
CE clinical efﬁcacy population, CI conﬁdence interval,MITT modiﬁed intent-to-treat population, MITTE modiﬁed intent-
to-treat efﬁcacy population, Vanc/Az vancomycin plus aztreonam combination
a Non-inferiority margin was set at -10% for both FOCUS and CANVAS trials
b Treatment difference: cure rate ceftaroline - cure rate comparator group
c Weighted treatment difference
Infect Dis Ther (2013) 2:95–110 101
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94.4% receiving combination therapy
(difference -1.7, 95% CI -4.9% to 1.6%) at
TOC [47]. In bacteremic subjects, cure rates
were 84.6% (22 of 26 subjects) in the
ceftaroline group compared to 100% (21 of 21
subjects) in the combination group (difference
-15.4%, 95% CI -33.8% to 1.5%) [47]. In
particular, cure rates among subjects with
S. aureus bacteremia were lower in the
ceftaroline group (88.9%), but not statistically
different from the combination group (100%)
with, notably, twice as many subjects having S.
aureus bacteremia in the ceftaroline group than
in the combination group (18 vs. 9,
respectively). At late follow-up (21–35 days
after completion of therapy), clinical relapse
rates were similar in the CE population: 1.1%
and 0.9% in the ceftaroline and combination
groups, respectively [47]. Post hoc analysis
requested by the FDA to evaluate clinical
response with cessation of lesion spread and
apyrexia on day 3 of study therapy was
conducted in a subgroup of 797 subjects and
showed a weighted difference of 7.7% (95% CI
1.3–14.0%) in favor of ceftaroline [49].
SAFETY
The safety profile of ceftaroline fosamil was
evaluated in 1,740 participants and no
unexpected safety concerns were identified [5,
48, 50, 51]. In the integrated FOCUS analysis,
the most common adverse events occurring in
greater than 2% of subjects receiving ceftaroline
fosamil were diarrhea (4.2%), headache (3.4%),
insomnia (3.1%) and phlebitis (2.8%) [50]. In
the integrated CANVAS analysis, the most
common adverse events occurring in greater
than 2% of subjects receiving ceftaroline
fosamil were nausea (5.9%), headache (5.2%),
diarrhea (4.9%), pruritus (3.5%), rash (3.2%),
generalized pruritus (2.2%) and dizziness
(2.0%) [51]. Seroconversion to a positive direct
anti-globulin (Coombs) test for the pooled data
was higher in the ceftaroline group than
comparator groups (10.7% vs. 4.4%,
respectively), but was not associated with
clinical hemolytic anemia [48]. Potential
allergic reactions occurred in 5.4% of those
treated with ceftaroline fosamil compared with
8.5% of those treated with a comparator
regimen, 0.2% and 0.4% of these reactions
were assessed as severe, respectively [48] Renal
toxicity occurred in less than 2% and hepatic
toxicity in less than 3% of those treated with
ceftaroline fosamil. Clostridium difficile-
associated diarrhea and seizures were reported,
but were rare [48].
Investigation of the effect of ceftaroline on
human intestinal flora in adults who received
infusions of ceftaroline fosamil IV every 12 h for
7 days revealed moderate decreases in the
numbers of bifidobacteria and lactobacilli,
with converse increases in the numbers of
Clostridium spp., but minimal to no impact on
Bacteroides spp. and aerobic bacteria [52]. Toxin-
producing strains of C. difficile were isolated
from two asymptomatic subjects. No
measurable fecal concentrations of ceftaroline
were found, which may have helped to explain
the limited ecological disruptions observed [52].
At a dose of 1,500 mg, there was no clinically
meaningful effect of ceftaroline fosamil on the
QT interval [53]. There is no evidence of
teratogenicity in animal studies, but controlled
studies in pregnant or lactating women have
not been performed [5]. Recently, isolated cases
of eosinophilic pneumonia [54] and
neutropenia [55] have been reported in
patients receiving prolonged courses of
ceftaroline; both events have been previously
documented with cephalosporin use [56–60].
Overall, the cumulative data to date suggest
102 Infect Dis Ther (2013) 2:95–110
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that ceftaroline is well tolerated with a favorable




There is a need for alternative antimicrobials that
can safely and effectively treat common but
serious bacterial infections, such as complicated
skin and skin structure infections and CABP
caused by emergent antibiotic-resistant
pathogens. In 2005, there were over 14 million
outpatient visits made in the USA for ABSSSIs
[61], which were among the most rapidly
increasing reasons for hospitalizations between
1997 and 2007 [62–64], correlating with the
rapid increase in the incidence of community-
acquired MRSA infections between the mid-
1990s and 2005 [65]. There has been a great
reliance on the glycopeptide, vancomycin, to
treat MRSA, one of the most common pathogens
associated with ABSSSIs, but resistant strains,
including vancomycin-resistant S. aureus (VRSA)
and VISA, have emerged [66]. In addition, the
rate of treatment failure is higher in strains with
an MIC of 1 lg/mL or greater, which includes
some strains that would be classified as
susceptible using current guidelines [67].
Vancomycin may also be inferior to b-lactam
antibiotics for the treatment of methicillin-
susceptible S. aureus bacteremia [68]. Other
FDA-approved antibiotics for the treatment of
MRSA include linezolid, daptomycin,
tigecycline and telavancin. There have been
reports of S. aureus treatment failures with
daptomycin and linezolid [66] and toxicities
associated with some of these options, such as
myelosuppression myopathy and
nephrotoxicity, are potentially limiting [69–
71]. Ceftaroline is a safe and effective option for
the parenteral treatment of skin and soft tissue
infections, especially in cases where empiric
MRSA and common Gram-negative coverage
are desired.
Pneumonia, another common but
potentially life-threatening infection, together
with influenza, consistently rank among the top
ten leading causes of death for all ages in the
USA each year, and accounted for more than 1.2
million hospitalizations in 2006 [72, 73].
Antibiotic susceptibility of S. pneumoniae, the
most common cause of CABP, has decreased in
the USA over the past decade. In 2009, only
84.1%, 87.5% and 60.8% of surveyed
S. pneumoniae isolates remained susceptible to
penicillin, ceftriaxone and erythromycin,
respectively [74]. Ceftaroline is active against
resistant Gram-positive pathogens and is a safe,
well-tolerated alternative option for the
parenteral treatment of CABP. Recently, the
incidence of pneumonia due to community-
associated MRSA has increased [46].
Ceftaroline’s major important advantage
compared to other b-lactam antibiotics, such
as ceftriaxone, is its activity against MRSA.
Although ceftaroline fosamil is approved for
the treatment of adults with ABSSSI caused by
MRSA, there are no official data to support its
use in the specific treatment of CABP caused by
MRSA. An experimental pneumonia model
demonstrated significantly decreased bacterial
counts in the lungs of neutropenic mice,
suggesting the possible usefulness of
ceftaroline for the treatment of MRSA
pneumonia [6]. A trial of ceftaroline fosamil
compared to ceftriaxone plus vancomycin in
adults with CABP and at risk for MRSA infection
is currently recruiting participants
(NCT01645735) and will hopefully provide the
clinical efficacy data needed to answer this
question.
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No pharmacoeconomic analyses on the cost
effectiveness of ceftaroline compared to other
agents are available. Using average wholesale
prices in US dollars, the approximate cost for a
10-day course of ceftaroline (600 mg IV twice
daily at $119.96/day) in a patient with normal
renal function seems comparable to the range
of costs for a similar course of other
antibiotics with MRSA activity, including
vancomycin (1 g IV twice daily at $9.40/day),
linezolid (600 mg IV twice daily at $288.8/
day), daptomycin (500 mg IV once daily at
$362.51/day) and tigecycline (100 mg IV once
daily or 50 mg IV twice daily at $208.76/day)
[75]. Given the lack of clinical data in specific
patient populations (such as those with MRSA
pneumonia and bacteremia) and the
demonstration of non-inferiority, rather than
superiority, in phase 3 trials [44, 47],
ceftaroline cannot currently be recommended
over other alternative therapies for the
treatment of CABP and ABSSSI, but should at
least be considered in situations where
concerns of resistance or toxicities may limit
the use of other available drugs.
Future Considerations
Although ceftaroline has limited activity
against resistant Gram-negative pathogens,
time–kill experiments suggest extended
coverage against resistant Enterobacteriaceae
when combined with a b-lactamase inhibitor
[76]. In vitro and animal studies demonstrated
that avibactam, a non-b-lactam b-lactamase
inhibitor, has potent synergistic activity with
ceftaroline [29, 77–80]. Avibactam appears to
inhibit ESBLs, including cephalosporinases and
carbapenemases, and so may potentially
enhance ceftaroline’s spectrum of activity
against Gram-negative bacteria. The
development of a combination that offers such
broad coverage is an exciting option for single-
agent treatment of empiric or polymicrobial
infections caused by multidrug-resistant
Enterobacteriaceae and MRSA [81].
Ceftobiprole, another new generation
cephalosporin approved for use in some
countries for the treatment of complicated
skin and soft tissue infections (however,
rejected by the FDA in 2009 and the European
Medicines Agency in 2010) has extended Gram-
positive activity similar to that of ceftaroline,
and Gram-negative coverage similar to that of
ceftazidime, but unlike ceftaroline–avibactam,
ceftobiprole remains susceptible to hydrolysis
by several ESBLs [82, 83]. Ceftaroline–avibactam
was well tolerated in a phase 1 trial without
demonstrating significant PK interaction when
administered concomitantly [84]. A phase 2
trial for the treatment of complicated urinary
tract infections (NCT01281462) has been
completed.
Animal models have been established to
evaluate the in vivo efficacy of ceftaroline in
the treatment of endocarditis, osteomyelitis and
meningitis [8, 9, 24, 85, 86]. Following a 4-day
course of ceftaroline fosamil in a rabbit
endocarditis model, ceftaroline demonstrated
superior bactericidal activity against MRSA and
heterogeneous VISA when compared to
vancomycin and linezolid [9]. Similarly,
ceftaroline fosamil demonstrated significant
bactericidal activity against MRSA and VISA,
with a greater than 5 log10 colony-forming
unit/g reduction of vegetation, which was
comparable to that of daptomycin and
superior to that of tigecycline [24]. When
compared to vancomycin and linezolid,
ceftaroline demonstrated improved bacterial
killing of vancomycin-sensitive and
vancomycin-resistant E. faecalis in both time–
kill experiments and a rabbit endocarditis
model [8]. Significant colony count reductions
104 Infect Dis Ther (2013) 2:95–110
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in infected joint and bone tissues were seen
following a 4-day course of ceftaroline in an
experimental rabbit model of acute MRSA
osteomyelitis, which was comparable to that
of linezolid and significantly better than that of
vancomycin, indicating ceftaroline has good
bone and joint penetration [85]. Ceftaroline was
superior to cefepime against Klebsiella
pneumoniae in a rabbit meningitis model; the
penetration of ceftaroline into inflamed and
non-inflamed meninges was estimated to be
15% and 3%, respectively [86].
Reports of off-label use of ceftaroline are also
emerging. Prompt sterilization of blood
following the addition of ceftaroline salvage
therapy was documented in a review of six cases
of persistent or recurrent MRSA bacteremia/
endocarditis being treated with vancomycin or
daptomycin [87, 88]. Interestingly, the five
patients treated with a more aggressive
regimen of ceftaroline 600 mg administered
every 8 h all survived, while the patient who
received ceftaroline every 12 h succumbed to
other complications [87]. A case report
documented clearance of blood within 4 days
of the addition of ceftaroline in a patient with
endocarditis failing daptomycin therapy, and is
supported by an in vitro PK/PD model, which
showed that the addition of ceftaroline
enhances daptomycin susceptibility [88]. A
similar PK/PD model showed that ceftaroline
increases membrane binding and enhances the
activity of daptomycin against daptomycin-
susceptible and non-susceptible strains of
MRSA, suggesting potency of this combination
[89]. Ceftaroline has also been used for the
treatment of prosthetic joint infections [90] and
in a patient with osteomyelitis and endocarditis
[91]. Though clinical data on the use of
ceftaroline for the treatment of infections
other than CABP and ABSSSI are lacking,
cumulatively, these in vivo animal studies and
case reports provide early evidence that
ceftaroline may potentially prove useful in the
treatment of other serious bacterial infections.
Due to insufficient safety, PK and efficacy
data, antibiotic options with MRSA activity in
children are even more limited than in the adult
population [92]. Pediatric trials evaluating the
safety and efficacy of ceftaroline for the
treatment of CABP and complicated skin
infections are currently recruiting patients
(NCT01530763, NCT01669980 and
NCT01400867). A cephalosporin with anti-
MRSA activity may prove valuable, as b-lactam
antibiotics are a popular choice for the
treatment of infections in children, given their
favorable safety profiles. As these and other
post-marketing studies are underway, other
areas to systematically address in the future
include the effectiveness of ceftaroline in the
treatment of immunocompromised patients,
patients with septic shock and those with
necrotizing fasciitis. Ongoing surveillance
studies will also be necessary.
CONCLUSION
Ceftaroline fosamil is a well-tolerated and
welcome addition to the available antibiotic
options for the treatment of the increasing
number of resistant Gram-positive and
common Gram-negative infections. Clinical
trials have demonstrated that the efficacy of
ceftaroline fosamil is similar to that of
comparator agents in the treatment of ABSSSI
and CABP. Its lack of activity against resistant
Gram-negative pathogens limits its current use
as a monotherapeutic agent for the treatment of
hospital-acquired infections, but with the
addition of a b-lactamase inhibitor, such as
avibactam, its activity may prove to be safely
extended. Additional trials to further define the
Infect Dis Ther (2013) 2:95–110 105
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efficacy of ceftaroline in the treatment of other
serious bacterial infections will be beneficial, as
will safety and efficacy data in children.
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